Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

Leukemia volume 28, pages 1738–1742 (2014)Cite this article

Subjects

STAT5 has an important role in many hematologic malignancies, but constitutive activation is often a secondary event.1 Mutations to STAT5B and their functional significance were recently discovered in large granular lymphocytic (LGL) leukemia.2 The mutations located in the SRC homology 2 (SH2) domain of STAT5B lead to constitutive phosphorylation of the mutant protein, increased transcriptional activity and activation of downstream target genes. However, activating mutations in STAT5B have thus far not been described in other cancers. In T-cell acute lymphoblastic leukemia (T-ALL), a complex cooperation of multiple oncogenic aberrations leads to the development of the disease.3 Approximately 9% of childhood T-ALL patients display IL7R gain-of-function mutations leading to constitutive activation of downstream targets.4 The two main pathways induced by IL7R are PI3K/AKT/MTOR and JAK/STAT5.5 In addition to mutations in IL7R, somatic JAK1 and JAK3 gain-of-function mutations are relatively prevalent in T-ALL presenting in 10.4% and 7% of adult patients, respectively.6, 7 Activating mutations to IL7R, JAK1, JAK2 or JAK3 are estimated to occur in 20–30% of all T-ALL patients.8 In naive T cells the stimulation of either JAK–STAT5 or PI3K pathway results in the induction of key anti-apoptotic factors, including B-cell lymphoma 2 (BCL-2) and myeloid cell leukemia sequence 1 (MCL1), while pro-apoptotic BCL-2 family members are inhibited.9 In T-ALL, however, the STAT5 target genes are inadequately known. Here we report the identification of activating mutations to STAT5B in T-ALL accompanied by overexpression of BCL-XL (BCL2L1) and sensitivity to pan-BCL-2 inhibitors.

Ex vivo drug sensitivity of BM blast cells from the index patient sampled at relapse was assessed against a comprehensive set of 264 approved and investigational drugs representing both targeted and chemotherapeutic drugs as previously described.11 In short, the drugs were pre-plated in 384-well plates over a 10 000-fold concentration range (for example, 1–10 000 nM), with 10 000 cells added to each well. After a 3-day incubation at 37 °C, cell viability was measured using the CellTiter-Glo reagent (Promega, Madison, WI, USA). Dose–response curves for each drug were generated for the patient cells and BM mononuclear cell fractions from three healthy donors, which served as controls. Results from the assay showed that the index patient blast cells were sensitive to the pan-BCL-2 family protein inhibitor navitoclax (EC50 81.9 nM) as well as to corticosteroids and mitogen-activated protein kinase kinase (MEK) inhibitors (Figure 2c). The blasts did not display sensitivity (EC50 ⩾1 μM) to Janus kinase (JAK) inhibitors (ruxolitinib and tofacitinib), RAC-alpha serine/threonine-protein kinase (AKT1) inhibitors (MK-2220), phosphoinisitide 3-kinase (PI3K) inhibitors (for example, idelalisib and XL147), dual inhibitors of PI3K and mammalian target of rapamycin (MTOR) (PF-04691502 and dactolisib) and rapalogs (temsirolimus and everolimus).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Yamada K, Ariyoshi K, Onishi M, Miyajima A, Hayakawa F, Towatari M et al. Constitutively active STAT5A and STAT5B in vitro and in vivo: mutation of STAT5 is not a frequent cause of leukemogenesis. Int J Hematol 2000; 71: 46–54.

    CAS  PubMed  Google Scholar 

  2. Rajala HL, Eldfors S, Kuusanmaki H, van Adrichem AJ, Olson T, Lagstrom S et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013; 121: 4541–4550.

    Article  CAS  Google Scholar 

  3. De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet 2013; 45: 186–190.

    Article  CAS  Google Scholar 

  4. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932–939.

    Article  CAS  Google Scholar 

  5. Ribeiro D, Melao A, Barata JT . IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013; 53: 211–222.

    Article  CAS  Google Scholar 

  6. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751–758.

    Article  CAS  Google Scholar 

  7. Bains T, Heinrich MC, Loriaux MM, Beadling C, Nelson D, Warrick A et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2144–2146.

    Article  CAS  Google Scholar 

  8. De Keersmaecker K, de Bock CE, Cools J . The biology of T-cell acute lymphoblastic leukemia. Hematology Education: the Education Program for the Annual Congress of the European Hematology Association, Vol 7, European Hematology Association 2013; pp 1–7.

  9. Takada K, Jameson SC . Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol 2009; 9: 823–832.

    Article  CAS  Google Scholar 

  10. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905–1913.

    Article  CAS  Google Scholar 

  11. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A et al. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3: 1416–1429.

    Article  CAS  Google Scholar 

  12. Kelly JA, Spolski R, Kovanen PE, Suzuki T, Bollenbacher J, Pise-Masison CA et al. Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J Exp Med 2003; 198: 79–89.

    Article  CAS  Google Scholar 

  13. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013; 3: 564–577.

    Article  CAS  Google Scholar 

  14. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA . Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004; 200: 659–669.

    Article  CAS  Google Scholar 

  15. Nelson EA, Walker SR, Alvarez JV, Frank DA . Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem 2004; 279: 54724–54730.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the patients who participated in the study. We acknowledge personnel of the High Throughput Biomedicine Unit and Minna Suvela, Pekka Ellonen, Aino Palva, Pirkko Mattila and Henrikki Almusa from Institute for Molecular Medicine Finland (FIMM) Technology Centre, University of Helsinki for their expert technical assistance. The Finnish Cancer Societies, Blood Disease Foundation, Finnish Association of Hematology, Orion-Farmos Research Foundation, Academy of Finland, Finnish Funding Agency for Technology and Innovation, and European Regional Development Fund supported this work.

Author information

Author notes

  1. M Kontro and H Kuusanmäki: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Medicine, Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland

    M Kontro, H Kuusanmäki, E I Andersson, H Rajala, S Mustjoki & K Porkka

  2. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

    H Kuusanmäki, S Eldfors, H Edgren, S Lagström, J M L Martí, M M Majumder, A Parsons, T Pemovska, O Kallioniemi & C A Heckman

  3. Department of Hematology, Oncology, and Tumor Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany

    T Burmeister

  4. Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway

    Ø Bruserud & B T Gjertsen

  5. Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway

    Ø Bruserud & B T Gjertsen

  6. Department of Oncology, Hematology and Stem Cell Transplantation, University Hospital Aachen, RWTH Aachen University, Aachen, Germany

    T H Brümmendorf

  7. Department of Clinical Hematology, Turku University Central Hospital, University of Turku, Turku, Finland

    M Itälä-Remes

  8. Tampere Center for Child Health Research, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland

    O Lohi

  9. Department of Clinical Chemistry and TYKSLAB, Turku University Central Hospital, University of Turku, Turku, Finland

    T Lundán

  10. Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland

    K Vettenranta

  11. Institute of Biomedicine, University of Helsinki, Helsinki, Finland

    C A Heckman

Authors
  1. M Kontro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kuusanmäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Eldfors
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Burmeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E I Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ø Bruserud
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T H Brümmendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Edgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B T Gjertsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Itälä-Remes
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Lagström
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. O Lohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Lundán
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J M L Martí
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M M Majumder
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. T Pemovska
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H Rajala
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. K Vettenranta
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. O Kallioniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. S Mustjoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. K Porkka
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. C A Heckman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C A Heckman.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

MK and HK designed the study, analyzed the data and wrote the manuscript; MK collected most of the sample material; HK performed most of the experiments; SE, HE and JMLM performed sequencing data analysis; TP and MMM performed drug sensitivity testing and corresponding analysis; EIA, SL, HR, MMM and AP performed the experiments and participated in the data analysis; TB, ØB, THB, BTG, OL, TL and KV provided the patient specimens and clinical data; and OK, SM, KP and CAH conceived the study, supervised the work and wrote the manuscript. All authors contributed to and approved the final manuscript.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kontro, M., Kuusanmäki, H., Eldfors, S. et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 28, 1738–1742 (2014). https://doi.org/10.1038/leu.2014.89

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.89

This article is cited by

Search

Advanced search

Quick links